What is Intensity Therapeutics, Inc.'s market cap?

Intensity Therapeutics, Inc. (INTS) has a market capitalization of $12.4M and trades on NASDAQ.

Who are Intensity Therapeutics, Inc.'s competitors?

Intensity Therapeutics, Inc.'s key competitors include Amgen, Replimune Group, Instil Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Intensity Therapeutics, Inc. partner with?

Intensity Therapeutics, Inc.'s notable partners include Merck & Co., Bristol Myers Squibb, Swiss Cancer Group.

Where is Intensity Therapeutics, Inc. headquartered?

Intensity Therapeutics, Inc. is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2023.

Intensity Therapeutics, Inc.

INTS

Intensity Therapeutics is a late-stage clinical biotechnology company focused on localized cancer reduction and anti-cancer immune activation.

Market cap

$12.35M+55.3%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

EPS-$0.96Beat by $0.23

Read the full report

Next report

Aug 6, 2026 (In 1 week)

EPS estimate-$0.87

Competitors

By market cap

Amgen$203.07B+25.3%

Oric Pharmaceuticals, Inc.$1.2B+30.6%

Replimune Group$724.4M+194%

Immuneering Corporation$282.1M+100%

NTH

Neonc Technologies Holdings, Inc.$89.2M-13.3%

CTO

Citius Oncology, Inc.$51.7M-64.7%

Instil Bio$48.5M-75.1%

Intensity Therapeutics, Inc.$12.4M+40.2%

By net margin

Amgen20.96%+3.6pp

NTH

Neonc Technologies Holdings, Inc.-51,613.33%—

Profile

Intensity Therapeutics is a late-stage clinical biotechnology company focused on localized cancer reduction and anti-cancer immune activation. The company utilizes its proprietary DfuseRx discovery platform to create intratumoral therapies that overcome the delivery challenges of the tumor microenvironment. Its lead candidate is designed to disperse cytotoxic agents directly into tumors to induce local cell death and systemic immune response.

Competitive position

A late-stage clinical developer utilizing a unique amphiphilic molecule platform to improve the efficacy of intratumoral drug delivery compared to traditional aqueous-based treatments.

GeographiesUnited States, Canada, Europe, Australia

Customer segmentsPatients, Healthcare Providers

Business modelR&D, IP Licensing

SuppliersBulk chemical suppliers, Contract Research Organizations (CROs), Generic drug manufacturers

CustomersOncology clinics, Hospitals, Strategic pharmaceutical partners

CountryUnited States of America

Listed2023

Employees17.0

CEOLewis H. Bender

SectorHealthcare

IndustryBiotechnology

Websiteintensitytherapeutics.com

FilingsSEC EDGAR

Questions, answered.

What is Intensity Therapeutics, Inc.'s market cap?: Intensity Therapeutics, Inc. (INTS) has a market capitalization of $12.4M and trades on NASDAQ.
Who are Intensity Therapeutics, Inc.'s competitors?: Intensity Therapeutics, Inc.'s key competitors include Amgen, Replimune Group, Instil Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Intensity Therapeutics, Inc. partner with?: Intensity Therapeutics, Inc.'s notable partners include Merck & Co., Bristol Myers Squibb, Swiss Cancer Group.
Where is Intensity Therapeutics, Inc. headquartered?: Intensity Therapeutics, Inc. is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2023.